Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurofibroma × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 79 Leukemia 45 Gastrointestinal Stromal Tumors 37 Leukemia, Myeloid, Chronic-Phase 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Blast Crisis 14 Philadelphia Chromosome 13 Brain Neoplasms 11 Lung Neoplasms 9 Gliosarcoma 9 Glioblastoma 9 Leukemia, Myeloid, Acute 8 Sarcoma 7 Leukemia, Myeloid, Accelerated Phase 7 Glioma 7 Prostatic Neoplasms 6 Oligodendroglioma 6 Neoplasms 6 Neoplasm Metastasis 6 Dermatofibrosarcoma 6 Small Cell Lung Carcinoma 5 Melanoma 5 Central Nervous System Neoplasms 5 Astrocytoma 5 Stomach Neoplasms 4 Recurrence 4 Primary Myelofibrosis 4 Ovarian Neoplasms 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Myeloid 4

Interventions

tipifarnib 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 Vincristine 1 Temozolomide 1 Sirolimus 1 Ranibizumab 1 Radiosurgery 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡